Biocept, Inc. (NASDAQ: BIOC)
Last week, I wrote an article about Biocept, explaining that I believe the stock is starting to turn bullish once again. Technical data told me that a breakout was coming soon while fundamental data tells me that this is a long term stock. Well, today, BIOC seems to be making good on my prediction. So, we’ll take a look at the breakout, discuss fundamental data, and talk about why I believe that this one will continue growing for the long run. Let’s get right to it…
Biocept Stock Is Climbing
Biocept is having a great day in the market today. After a relatively flat week last week, investors seem to have picked this one up today in early morning trading. Currently (10:48), the stock is trading at $3.05 per share after a gain of 5.17% so far today.
Why We’re Seeing The Climb
I did a bit of research, looking for a piece of data that surfaced today that would have caused the climb. However, that search came up empty. Instead, I think that investors are finally picking up the good news we’ve been seeing lately surrounding the stock, coupling it with the technical data, and driving the price up. Lately, there have been two big announcements from BIOC…
- Breast Cancer – Recently, Biocept released data from a study that focused on the diagnosis of breast cancer. The study compared the results of blood test biopsies to the results of traditional tissue biopsies; finding that Biocept’s liquid biopsy was just as effective in diagnosing certain types of breast cancer.
- Lung Cancer – Biocept also recently released data revolving around a new test that is designed for the early detection of lung cancer. Using a simple blood test, Biocept is now able to tell patients if they are likely to develop lung cancer in the future.
Both of these news releases are incredibly important for Biocept, it’s investors, and the cancer industry as a whole. Considering the fact that the company has been able to detect cancer using a simple blood test, patients may not have to deal with invasive tissue biopsies in the future. Also, by being able to determine if a patient is likely to develop lung cancer in the future, Biocept can increase the rate at which lung cancer is detected early; ultimately increasing survival rates. All in all, it’s clear that the company is focused on early detection, and has a clear path to success!
What To Expect To See From BIOC Moving Forward
Moving forward, I’m expecting to see great growth out of BIOC. Personally, I’m incredibly impressed with what the company has been able to accomplish with regard to the diagnosis of cancer. I’d also have to imagine that the company will continue to expand its testing capabilities to assist in the early detection of far more cancers in the future. With sound management, a great line up of tests, and the willingness to continue innovating new, exciting things for the medical industry, I couldn’t imagine this stock going anywhere, but up in the long run. However, I think that it’s important for investors to remember that BIOC is a small-cap biotech stock. So, we’re likely to see heavy volatility on the way to the top.
What Do You Think?
Where do you think BIOC is headed and why? Let us know in the comments below!